RELATED STUDY

Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages

Key Findings:  CBD, CBG and THCV may have clinical value in reducing cytokine secretion in lung epithelial cell however, an extract of a cannabis chemotype III (abundant in CBD) containing various terpenes increased pro-inflammatory cytokine production. As such the authors posit that, that for now, cannabinoid-based therapeutics ought to be avoided in the treatment or prevention of COVID-19.

Type of Study:  Laboratory Study

Study Result:  Inconclusive

Study Location(s):  Israel

Year of Pub:  2021


Cannabinoids Studied:  Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabivarin (THCV)

Phytocannabinoid Source:  Cannabis Flower derived

Chemotype:  Chemotype III

Route of Administration:  In vitro



Link to study